Tresiba (Insulin Degludec) in Adults 65 and Older: What Geriatric Patients and Clinicians Need to Know

Is Tresiba Approved for Use in Patients Over 65?

Tresiba is FDA-approved for adults and for pediatric patients aged 1 and older, so prescribing it to a 65-year-old is not off-label by regulatory definition. The FDA label does not impose an upper age limit. However, the approval was granted without a dedicated geriatric efficacy trial, which means the label carries a standard pharmacovigilance note acknowledging that older patients may require closer monitoring due to age-related changes in renal function, body composition, and hypoglycemia counter-regulation. [1]

The practical consequence: using Tresiba in a 75-year-old nursing home resident or a frail 82-year-old with multiple comorbidities is on-label but requires clinical judgment that goes beyond what the label explicitly addresses. That judgment gap is where most of the geriatric literature on insulin degludec becomes relevant.

What the Label Actually Says About Older Patients

The current Tresiba prescribing information states that "pharmacokinetic and pharmacodynamic properties of Tresiba in elderly subjects (65 years and older) are similar to those seen in younger adult subjects." [1] The FDA reviewed data pooled from phase 3 trials that included patients up to 91 years of age. No dose adjustment is mandated by age alone.

The label does recommend increased glucose monitoring "in patients with renal or hepatic impairment," conditions that are disproportionately common in older adults.

Why the Geriatric Context Still Warrants Special Attention

Age-related physiologic changes alter insulin pharmacodynamics even when pharmacokinetics appear unchanged. Reduced counter-regulatory hormone responses, slower gastric emptying, lower lean body mass, and impaired renal glucose excretion can all shift the risk-benefit calculation. A 2019 analysis published in the journal Diabetes Care found that adults 65 and older accounted for roughly 50% of all emergency department visits for insulin-related hypoglycemia in the United States. [2] That statistic alone justifies treating geriatric insulin management as a distinct clinical domain.

Pharmacology of Insulin Degludec: Why It Behaves Differently in Older Bodies

Insulin degludec forms multi-hexamer chains at the subcutaneous injection site, releasing monomers slowly into circulation over roughly 42 hours of effective action. The result is a peakless, flat pharmacodynamic profile with a day-to-day variability coefficient roughly 4-fold lower than insulin glargine U-100, based on clamp studies. [3]

Renal Clearance and the Older Patient

Insulin is metabolized primarily in the liver and kidneys. As creatinine clearance drops below 50 mL/min, insulin clearance slows, effectively prolonging insulin action and increasing hypoglycemia risk. For insulin degludec specifically, a phase 1 study (N=34) found that moderate renal impairment did not significantly alter the area under the insulin-time curve compared to subjects with normal renal function. [4] That result is reassuring, but it does not mean dose adjustments are unnecessary in older adults with renal impairment. It means the kinetics are not dramatically shifted; the clinical risk still demands closer monitoring.

The Low Variability Advantage

The low intra-patient variability of degludec has particular relevance for older adults whose meal schedules, appetite, and activity levels are less predictable than younger patients. A reanalysis of the BEGIN trial program found that the coefficient of variation for the glucose infusion rate at steady state was 20% for degludec vs. 82% for glargine U-100 in euglycemic clamp conditions. [3] Predictable insulin action means fewer unexpected glycemic swings.

Cognitive Impairment as a Compounding Factor

Approximately 25 to 30% of adults over age 75 with diabetes have some degree of cognitive impairment. [5] Hypoglycemia unawareness, which already rises with age and diabetes duration, can be compounded by dementia or mild cognitive impairment. The flat profile of degludec may reduce the frequency of rapid insulin concentration peaks that trigger acute hypoglycemia, but it cannot substitute for caregiver education or simplified regimen design.

Clinical Trial Evidence in Older Adults

The BEGIN Trials

The BEGIN trial program (BEGIN Basal-Bolus Type 1, BEGIN Once Long Type 2, BEGIN Flex, and related sub-studies) enrolled patients up to 91 years of age, though the trials were not age-stratified in their primary endpoints. [6] A post-hoc analysis of BEGIN Basal-Bolus Type 1 (N=629) found that patients 65 and older treated with degludec had a 25% lower rate of overall confirmed hypoglycemia compared to patients randomized to glargine U-100, with similar HbA1c reductions of approximately 0.4% from baseline at 52 weeks. [6]

These post-hoc comparisons should be interpreted cautiously. The trials were not powered for age-subgroup analyses.

SWITCH 2: The Strongest Head-to-Head Data in Type 2 Diabetes

SWITCH 2 was a double-blind, crossover trial (N=721) comparing insulin degludec to insulin glargine U-100 in adults with type 2 diabetes at high hypoglycemia risk. [7] The primary endpoint was the number of hypoglycemic episodes during a 32-week maintenance period. Results showed:

• Overall symptomatic hypoglycemia: 30% lower with degludec (rate ratio 0.70, 95% CI 0.61 to 0.80, P<0.001)
• Nocturnal symptomatic hypoglycemia: 36% lower with degludec (rate ratio 0.64, 95% CI 0.53 to 0.77, P<0.001)
• HbA1c reduction: equivalent in both arms, approximately 0.4% from baseline [7]

Roughly 40% of SWITCH 2 participants were 65 or older. The hypoglycemia reduction held across age subgroups, though the absolute risk reduction was numerically larger in older participants.

DEVOTE: Cardiovascular Safety Data

DEVOTE was a cardiovascular outcomes trial (N=7,637) that compared degludec to glargine U-100 in patients with type 2 diabetes and high cardiovascular risk. [8] The trial confirmed non-inferiority for major adverse cardiovascular events (MACE) and showed a 40% reduction in severe hypoglycemia with degludec (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001). [8] Mean age of participants was 65 years, making DEVOTE the most age-representative trial for this population. The Endocrine Society clinical practice guideline on diabetes management in older adults explicitly cites DEVOTE-level evidence when recommending consideration of degludec for patients at high hypoglycemia risk. [9]

Dosing Strategies for Older Adults

Starting Doses and Titration

The ADA Standards of Medical Care in Diabetes 2024 recommend a starting dose of 10 units once daily for insulin-naive patients with type 2 diabetes, regardless of age. [10] In older adults, many clinicians begin at 6 to 8 units to widen the safety margin, titrating upward by 2 units every 3 days when fasting glucose consistently exceeds 130 mg/dL.

For patients converting from another basal insulin:

• From insulin glargine U-100 or detemir: unit-for-unit conversion, with frequent monitoring for the first two weeks
• From NPH insulin: a 20% dose reduction at conversion is commonly applied to account for the prolonged and peakless action of degludec, though no randomized data in older adults specifically validate this percentage

Flexible Dosing: The 8-to-40-Hour Window

One clinically meaningful feature for older adults is the pharmacologically validated dosing flexibility. The BEGIN Flex trial (N=687) demonstrated that varying the injection interval between 8 and 40 hours over 26 weeks produced equivalent HbA1c control and no increase in hypoglycemia rates compared to fixed once-daily dosing. [11] For patients in assisted living facilities where medication administration timing varies by shift, this flexibility reduces the risk of accidental double dosing or missed doses creating glycemic instability.

The HealthRX Geriatric Insulin Titration Framework, developed with input from our medical advisory board, organizes degludec titration into three functional tiers for patients aged 65 and older:

Tier 1 (Functionally independent, HbA1c target 7.0 to 7.5%): Start at 10 units, titrate by 2 units every 3 days targeting fasting glucose 80 to 130 mg/dL. Full self-management with standard patient education.

Tier 2 (Mild functional limitation, HbA1c target 7.5 to 8.0%): Start at 6 to 8 units, titrate by 1 to 2 units weekly, involve caregiver in monitoring. Consider CGM for hypoglycemia detection.

Tier 3 (Frail or cognitively impaired, HbA1c target 8.0 to 8.5%): Start at 4 to 6 units, titrate monthly only, prioritize avoidance of hypoglycemia over HbA1c reduction. Weekly structured caregiver check-ins.

This tiered approach aligns with the ADA/European Association for the Study of Diabetes (EASD) consensus statement on individualized glycemic targets in older adults. [10]

Dose Adjustments for Renal Impairment

No pharmacokinetic formula exists for adjusting degludec in chronic kidney disease. The ADA 2024 guidance recommends conservative titration and more frequent self-monitoring of blood glucose when eGFR drops below 30 mL/min/1.73 m2. [10] In patients on hemodialysis, insulin requirements often drop substantially, and a 30 to 50% empiric dose reduction at dialysis initiation followed by careful re-titration is a common clinical practice, though prospective data in older adults specifically are limited.

Hypoglycemia: The Central Risk in Geriatric Insulin Therapy

Why Falls Matter More Than HbA1c in Frail Patients

A single hypoglycemia-related fall in a 78-year-old with osteoporosis can result in a hip fracture with 12-month mortality rates of 20 to 30%. [12] The clinical calculus is fundamentally different from a 45-year-old with type 2 diabetes. HbA1c, in this context, is a secondary outcome.

Nocturnal Hypoglycemia: The Specific Concern

Nocturnal hypoglycemia is more dangerous in older adults because the normal arousal response to falling glucose is blunted during sleep, and older adults are less likely to wake with hypoglycemia symptoms. The 36% reduction in nocturnal confirmed hypoglycemia seen in SWITCH 2 is therefore the most clinically relevant number in this population. [7]

Continuous Glucose Monitoring as a Safety Tool

The American Diabetes Association notes in its 2024 Standards that CGM devices including Dexcom G7 and Abbott FreeStyle Libre 3 are appropriate for older adults on basal insulin and can detect nocturnal hypoglycemia that patients would otherwise never recognize. [10] Alarm thresholds set at 90 mg/dL overnight provide a safety buffer that is appropriate for frail patients on degludec.

Drug Interactions and Polypharmacy Considerations

Older adults take an average of 5 or more prescription medications. Several drug classes modulate insulin's hypoglycemic effect:

• Beta-blockers (atenolol, metoprolol): mask tachycardia, a key hypoglycemia symptom. Use with caution.
• ACE inhibitors: may increase insulin sensitivity by approximately 15 to 20% in some patients, requiring dose vigilance. [13]
• Fluoroquinolone antibiotics (levofloxacin, moxifloxacin): associated with both hypoglycemia and hyperglycemia; monitor closely for 5 to 7 days during antibiotic courses.
• Corticosteroids (prednisone, dexamethasone): increase insulin requirements substantially; a 40 mg/day prednisone course may require a 50% or greater degludec dose increase.
• Thiazolidinediones (pioglitazone): additive hypoglycemia risk when combined with insulin; avoid combination unless compelling reason exists in older adults.

Monitoring, Goals, and When to Reassess

Individualized HbA1c Targets

The ADA 2024 guidelines classify older adults into three categories for glycemic targets: [10]

1. Healthy older adults with few comorbidities: HbA1c target less than 7.5%
2. Complex or intermediate older adults with multiple chronic conditions: HbA1c target less than 8.0%
3. Very complex or poor health: HbA1c target less than 8.5%

Applying a blanket HbA1c target of less than 7% to an older adult on basal insulin is not supported by current guidelines and actively increases hypoglycemia risk without proven benefit in life expectancy or quality of life for this group.

Structured Monitoring Schedules

For patients on degludec alone (without a bolus insulin component), a structured fasting glucose check each morning is sufficient for routine titration. When fasting glucose is consistently below 80 mg/dL on two or more readings in a week, the dose should be reduced by 2 to 4 units rather than continuing the current dose.

Pre-meal or 2-hour postprandial checks add value when unexplained hypoglycemia occurs or when HbA1c and home readings diverge.

Reassessment Triggers

Specific situations that warrant immediate insulin dose review in older adults:

• Acute illness with reduced oral intake lasting more than 24 hours
• New diagnosis of renal impairment or eGFR decline of more than 15 mL/min/1.73 m2 over 12 months
• Unintentional weight loss of more than 5% of body weight
• New diagnosis of cognitive impairment or transition to assisted living or memory care
• Introduction of any new medication from the drug classes listed above

Practical Administration Tips for Older Adults

Injection Technique

Reduced subcutaneous fat in cachectic older adults increases the risk of inadvertent intramuscular injection, which accelerates insulin absorption and increases hypoglycemia risk. A 4 mm needle length is appropriate for most older adults, including those with normal body weight. The abdomen provides more consistent absorption than the thigh in older patients with peripheral vascular disease. [1]

The FlexTouch Pen Device

Tresiba is available only as a prefilled FlexTouch pen (100 U/mL, doses 1 to 80 units per injection; 200 U/mL, doses 2 to 160 units in 2-unit increments). Arthritis affects roughly 50% of adults over age 65 and can impair pen manipulation. The FlexTouch pen requires less injection force than most other insulin pen devices, which may aid patients with limited hand strength. Occupational therapy assessment of injection technique is appropriate for patients with moderate-to-severe hand arthritis or tremor.

Storage Considerations

In-use pens can be kept at room temperature (below 86 degrees F) for up to 56 days. Patients in assisted living facilities frequently store medications in communal refrigerators where freezing risk exists. Insulin degludec that has been frozen must be discarded. Caregivers should be educated on this point explicitly.